Pham MC et al. overcoming the study of polyclonal serum in patients with myasthenia gravis (MG) by producing several monoclonal antibodies (mAb) which target the nicotinic acetylcholine receptor (AchR) reporting that:
- The single autoreactive clones can react with different AChR subunit
- The AchR mAbs can mediate the disorder by complement activation, receptor blockade and antigenic modulation
- The pathogenic mechanisms are not mutually exclusive at the monoclonal level
- There is an association between the mAb specificity and the pathogenic capacity
This work is extremely relevant because expand the insight into the immunopathology of MG by demonstrating that the serum of MG patients may contain several antibodies targeting different AchR subunits with different pathogenic capacity.